Celularity Inc.
Rising onTrending downwardMoving on elevated volumeStrong bullish X conversation$1.85+17.1%1Y-27.5%
Mentions · last 7 days
0
Price updated 9h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $CELU, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $CELU.
Biotechnology
GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.
What this means for $CELU
Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-0.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-151%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-231%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-21.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
2.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
411%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
76.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
-1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-0.95$-1.50+36.7%
Q3 2025Nov 14, 2025$-0.88$-1.50+41.3%
Q2 2025Aug 29, 2025$-0.75——
Q1 2025May 8, 2025$-0.84$-1.50+44.0%
Next earningsFri, Nov 13
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$4.1M-77.4%208%-537%$-0.95$-5.1M
Q3 FY25$5.3M-43.2%61.8%-244%$-0.88$-4.2M
Q2 FY25$5.7M-52.6%8.6%-277%$-1.02$-999K
Q1 FY25$11.4M-22.2%68.9%-91.8%$-0.84$-3.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$44.0M$44.0M – $44.0M-$2.75-$2.75 – -$2.751
FY27$285.7M$285.7M – $285.7M$1.50$1.50 – $1.501
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.37%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+134.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+63.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 18.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today17.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.545-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeAug 78-K — Item 5.02: Officer or director change
AI summary
8-KListing / delisting noticeJul 298-K — Item 3.01: Listing / delisting notice
AI summary
8-KMaterial agreementJun 308-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 5.02: Officer or director change
AI summary
8-KOfficer or director changeJun 258-K — Item 5.02: Officer or director change
SC 13D/AActivist amendmentJun 23SC 13D/A
8-KListing / delisting noticeJun 128-K — Item 3.01: Listing / delisting notice
8-KOfficer or director changeJun 38-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KMaterial agreementMay 288-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
+ 13 other (3 3s · 3 8-Ks · 2 NT 10-Qs · 1 25-NSE) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® PlatformCelularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® PlatformCelularity Provides Update Regarding Nasdaq Listing ComplianceCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell TherapiesCelularity Releases CEO Letter to Shareholders
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 15 · last 7 days